#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Urine is a vital biofluid in mammals and could be easily collected in a noninvasive manner .
2-1	14-19	Urine	substance	new	coref	2-3[3_0]
2-2	20-22	is	_	_	_	_
2-3	23-24	a	substance[3]	giv[3]	coref	3-9[0_3]
2-4	25-30	vital	substance[3]	giv[3]	_	_
2-5	31-39	biofluid	substance[3]	giv[3]	_	_
2-6	40-42	in	substance[3]	giv[3]	_	_
2-7	43-50	mammals	substance[3]|animal	giv[3]|new	_	_
2-8	51-54	and	_	_	_	_
2-9	55-60	could	_	_	_	_
2-10	61-63	be	_	_	_	_
2-11	64-70	easily	_	_	_	_
2-12	71-80	collected	_	_	_	_
2-13	81-83	in	_	_	_	_
2-14	84-85	a	abstract[5]	new[5]	_	_
2-15	86-97	noninvasive	abstract[5]	new[5]	_	_
2-16	98-104	manner	abstract[5]	new[5]	_	_
2-17	105-106	.	_	_	_	_

#Text=Moreover , the metabolites components and concentrations in urine are good indicators of metabolic fluctuations .
3-1	107-115	Moreover	_	_	_	_
3-2	116-117	,	_	_	_	_
3-3	118-121	the	abstract[7]	new[7]	_	_
3-4	122-133	metabolites	substance|abstract[7]	new|new[7]	coref	19-1[124_0]
3-5	134-144	components	abstract[7]	new[7]	_	_
3-6	145-148	and	_	_	_	_
3-7	149-163	concentrations	abstract[8]	new[8]	coref	3-11[10_8]
3-8	164-166	in	abstract[8]	new[8]	_	_
3-9	167-172	urine	abstract[8]|substance	new[8]|giv	coref	6-15
3-10	173-176	are	_	_	_	_
3-11	177-181	good	abstract[10]	giv[10]	_	_
3-12	182-192	indicators	abstract[10]	giv[10]	_	_
3-13	193-195	of	abstract[10]	giv[10]	_	_
3-14	196-205	metabolic	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-15	206-218	fluctuations	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-16	219-220	.	_	_	_	_

#Text=Comparison of metabolite profiles between the treatment group and the control group could obtain metabolic changes and reveal adverse effects mechanism of stressor .
4-1	221-231	Comparison	abstract[12]	new[12]	_	_
4-2	232-234	of	abstract[12]	new[12]	_	_
4-3	235-245	metabolite	abstract[12]|substance|abstract[14]	new[12]|new|new[14]	_	_
4-4	246-254	profiles	abstract[12]|abstract[14]	new[12]|new[14]	_	_
4-5	255-262	between	abstract[12]	new[12]	_	_
4-6	263-266	the	abstract[12]|animal[16]	new[12]|new[16]	coref	10-7[78_16]
4-7	267-276	treatment	abstract[12]|abstract|animal[16]	new[12]|new|new[16]	coref	10-11
4-8	277-282	group	abstract[12]|animal[16]	new[12]|new[16]	_	_
4-9	283-286	and	abstract[12]	new[12]	_	_
4-10	287-290	the	abstract[12]|person[17]	new[12]|new[17]	_	_
4-11	291-298	control	abstract[12]|person[17]	new[12]|new[17]	_	_
4-12	299-304	group	abstract[12]|person[17]	new[12]|new[17]	_	_
4-13	305-310	could	_	_	_	_
4-14	311-317	obtain	_	_	_	_
4-15	318-327	metabolic	abstract[18]	new[18]	coref	6-11[32_18]
4-16	328-335	changes	abstract[18]	new[18]	_	_
4-17	336-339	and	_	_	_	_
4-18	340-346	reveal	_	_	_	_
4-19	347-354	adverse	abstract[19]|abstract[20]	new[19]|new[20]	_	_
4-20	355-362	effects	abstract[19]|abstract[20]	new[19]|new[20]	_	_
4-21	363-372	mechanism	abstract[20]	new[20]	_	_
4-22	373-375	of	abstract[20]	new[20]	_	_
4-23	376-384	stressor	abstract[20]|abstract	new[20]|new	_	_
4-24	385-386	.	_	_	_	_

#Text=In this study , 1H-NMR and UPLC-MS/MS based metabolomics were employed to investigate the metabolic perturbations after rac -metalaxyl and metalaxyl-M exposure .
5-1	387-389	In	_	_	_	_
5-2	390-394	this	abstract[22]	new[22]	_	_
5-3	395-400	study	abstract[22]	new[22]	_	_
5-4	401-402	,	_	_	_	_
5-5	403-409	1H-NMR	person	new	_	_
5-6	410-413	and	_	_	_	_
5-7	414-424	UPLC-MS/MS	abstract	new	_	_
5-8	425-430	based	abstract[25]	new[25]	_	_
5-9	431-443	metabolomics	abstract[25]	new[25]	_	_
5-10	444-448	were	_	_	_	_
5-11	449-457	employed	_	_	_	_
5-12	458-460	to	_	_	_	_
5-13	461-472	investigate	_	_	_	_
5-14	473-476	the	abstract[26]	new[26]	_	_
5-15	477-486	metabolic	abstract[26]	new[26]	_	_
5-16	487-500	perturbations	abstract[26]	new[26]	_	_
5-17	501-506	after	abstract[26]	new[26]	_	_
5-18	507-510	rac	abstract[26]|substance|event[28]	new[26]|new|new[28]	coref|coref	6-5[30_0]|11-5[0_28]
5-19	511-521	-metalaxyl	abstract[26]|event[28]	new[26]|new[28]	_	_
5-20	522-525	and	abstract[26]|event[28]	new[26]|new[28]	_	_
5-21	526-537	metalaxyl-M	abstract[26]|event[28]	new[26]|new[28]	_	_
5-22	538-546	exposure	abstract[26]|event[28]	new[26]|new[28]	_	_
5-23	547-548	.	_	_	_	_

#Text=The results showed that both rac -metalaxyl and metalaxyl-M induced systematic metabolic changes in urine and serum .
6-1	549-552	The	abstract[29]	new[29]	coref	13-1[98_29]
6-2	553-560	results	abstract[29]	new[29]	_	_
6-3	561-567	showed	_	_	_	_
6-4	568-572	that	_	_	_	_
6-5	573-577	both	substance[30]	giv[30]	coref	11-22[0_30]
6-6	578-581	rac	substance[30]	giv[30]	_	_
6-7	582-592	-metalaxyl	_	_	_	_
6-8	593-596	and	_	_	_	_
6-9	597-608	metalaxyl-M	substance	new	coref	7-4
6-10	609-616	induced	_	_	_	_
6-11	617-627	systematic	abstract[32]	giv[32]	coref	7-9[40_32]
6-12	628-637	metabolic	abstract[32]	giv[32]	_	_
6-13	638-645	changes	abstract[32]	giv[32]	_	_
6-14	646-648	in	abstract[32]	giv[32]	_	_
6-15	649-654	urine	abstract[32]|substance	giv[32]|giv	coref	19-10[128_0]
6-16	655-658	and	abstract[32]	giv[32]	_	_
6-17	659-664	serum	abstract[32]|substance	giv[32]|new	_	_
6-18	665-666	.	_	_	_	_

#Text=Rac -metalaxyl and metalaxyl-M induced liver damages and metabolic pathway changes including glycine , serine , and threonine metabolism , citrate cycle ( TCA cycle ) , pyruvate metabolism , glycolysis or gluconeogenesis , glycerophospholipid metabolism , and glyoxylate and dicarboxylate metabolism .
7-1	667-670	Rac	person	new	_	_
7-2	671-681	-metalaxyl	_	_	_	_
7-3	682-685	and	_	_	_	_
7-4	686-697	metalaxyl-M	substance	giv	coref	10-8[76_0]
7-5	698-705	induced	_	_	_	_
7-6	706-711	liver	object|event[38]	new|new[38]	coref|coref	9-6|16-1[117_38]
7-7	712-719	damages	event[38]	new[38]	_	_
7-8	720-723	and	_	_	_	_
7-9	724-733	metabolic	abstract[39]|abstract[40]	new[39]|giv[40]	coref	9-2[70_40]
7-10	734-741	pathway	abstract[39]|abstract[40]	new[39]|giv[40]	_	_
7-11	742-749	changes	abstract[40]	giv[40]	_	_
7-12	750-759	including	abstract[40]	giv[40]	_	_
7-13	760-767	glycine	abstract[40]|object|abstract[44]	giv[40]|new|new[44]	_	_
7-14	768-769	,	abstract[40]|abstract[44]	giv[40]|new[44]	_	_
7-15	770-776	serine	abstract[40]|substance|abstract[44]	giv[40]|new|new[44]	_	_
7-16	777-778	,	abstract[40]|abstract[44]	giv[40]|new[44]	_	_
7-17	779-782	and	abstract[40]|abstract[44]	giv[40]|new[44]	_	_
7-18	783-792	threonine	abstract[40]|object|abstract[44]	giv[40]|new|new[44]	_	_
7-19	793-803	metabolism	abstract[40]|abstract[44]	giv[40]|new[44]	_	_
7-20	804-805	,	abstract[40]	giv[40]	_	_
7-21	806-813	citrate	abstract[40]|substance|abstract[46]	giv[40]|new|new[46]	appos|coref	7-24[48_46]|19-20
7-22	814-819	cycle	abstract[40]|abstract[46]	giv[40]|new[46]	_	_
7-23	820-821	(	abstract[40]	giv[40]	_	_
7-24	822-825	TCA	abstract[40]|abstract|abstract[48]	giv[40]|new|giv[48]	coref|coref	20-12|20-11[141_48]
7-25	826-831	cycle	abstract[40]|abstract[48]	giv[40]|giv[48]	_	_
7-26	832-833	)	abstract[40]	giv[40]	_	_
7-27	834-835	,	abstract[40]	giv[40]	_	_
7-28	836-844	pyruvate	abstract[40]|abstract|abstract[50]	giv[40]|new|new[50]	coref	19-28
7-29	845-855	metabolism	abstract[40]|abstract[50]	giv[40]|new[50]	_	_
7-30	856-857	,	abstract[40]	giv[40]	_	_
7-31	858-868	glycolysis	abstract[40]|abstract	giv[40]|new	coref	20-19
7-32	869-871	or	abstract[40]	giv[40]	_	_
7-33	872-887	gluconeogenesis	abstract[40]|abstract	giv[40]|new	coref	20-21
7-34	888-889	,	abstract[40]	giv[40]	_	_
7-35	890-909	glycerophospholipid	abstract[40]|object|abstract[54]	giv[40]|new|new[54]	_	_
7-36	910-920	metabolism	abstract[40]|abstract[54]	giv[40]|new[54]	_	_
7-37	921-922	,	abstract[40]	giv[40]	_	_
7-38	923-926	and	abstract[40]	giv[40]	_	_
7-39	927-937	glyoxylate	abstract[40]|object|abstract[57]	giv[40]|new|new[57]	coref	8-7[60_57]
7-40	938-941	and	abstract[40]|abstract[57]	giv[40]|new[57]	_	_
7-41	942-955	dicarboxylate	abstract[40]|object|abstract[57]	giv[40]|new|new[57]	_	_
7-42	956-966	metabolism	abstract[40]|abstract[57]	giv[40]|new[57]	_	_
7-43	967-968	.	_	_	_	_

#Text=These pathways are highly related to energy metabolism , lipid metabolism , amino acids metabolism , microbial metabolism , and tryptophan metabolism .
8-1	969-974	These	abstract[58]	new[58]	coref	20-7[139_58]
8-2	975-983	pathways	abstract[58]	new[58]	_	_
8-3	984-987	are	_	_	_	_
8-4	988-994	highly	_	_	_	_
8-5	995-1002	related	_	_	_	_
8-6	1003-1005	to	_	_	_	_
8-7	1006-1012	energy	abstract|abstract[60]	new|giv[60]	coref|coref	8-10[62_60]|18-1
8-8	1013-1023	metabolism	abstract[60]	giv[60]	_	_
8-9	1024-1025	,	_	_	_	_
8-10	1026-1031	lipid	substance|abstract[62]	new|giv[62]	coref	8-13[65_62]
8-11	1032-1042	metabolism	abstract[62]	giv[62]	_	_
8-12	1043-1044	,	_	_	_	_
8-13	1045-1050	amino	object|substance[64]|abstract[65]	new|new[64]|giv[65]	coref	8-17[66_65]
8-14	1051-1056	acids	substance[64]|abstract[65]	new[64]|giv[65]	_	_
8-15	1057-1067	metabolism	abstract[65]	giv[65]	_	_
8-16	1068-1069	,	_	_	_	_
8-17	1070-1079	microbial	abstract[66]	giv[66]	coref	8-21[68_66]
8-18	1080-1090	metabolism	abstract[66]	giv[66]	_	_
8-19	1091-1092	,	_	_	_	_
8-20	1093-1096	and	_	_	_	_
8-21	1097-1107	tryptophan	object|abstract[68]	new|giv[68]	coref	15-10[0_68]
8-22	1108-1118	metabolism	abstract[68]	giv[68]	_	_
8-23	1119-1120	.	_	_	_	_

#Text=3.1. Body Weight Changes and Liver Damage
9-1	1121-1125	3.1.	_	_	_	_
9-2	1126-1130	Body	person[69]|abstract[70]|abstract[71]	new[69]|giv[70]|giv[71]	coref|coref	9-2[71_70]|11-7[82_71]
9-3	1131-1137	Weight	person[69]|abstract[70]|abstract[71]	new[69]|giv[70]|giv[71]	_	_
9-4	1138-1145	Changes	abstract[70]|abstract[71]	giv[70]|giv[71]	_	_
9-5	1146-1149	and	abstract[71]	giv[71]	_	_
9-6	1150-1155	Liver	abstract[71]|object|abstract[73]	giv[71]|giv|new[73]	coref	13-10
9-7	1156-1162	Damage	abstract[71]|abstract[73]	giv[71]|new[73]	_	_

#Text=Only one mouse was dead in the 60 mg/kg metalaxyl-M treatment group during the whole experiment .
10-1	1163-1167	Only	animal[74]	new[74]	_	_
10-2	1168-1171	one	animal[74]	new[74]	_	_
10-3	1172-1177	mouse	animal[74]	new[74]	_	_
10-4	1178-1181	was	_	_	_	_
10-5	1182-1186	dead	_	_	_	_
10-6	1187-1189	in	_	_	_	_
10-7	1190-1193	the	animal[78]	giv[78]	_	_
10-8	1194-1196	60	abstract[75]|substance[76]|animal[78]	new[75]|giv[76]|giv[78]	coref	12-8[0_76]
10-9	1197-1202	mg/kg	abstract[75]|substance[76]|animal[78]	new[75]|giv[76]|giv[78]	_	_
10-10	1203-1214	metalaxyl-M	substance[76]|animal[78]	giv[76]|giv[78]	_	_
10-11	1215-1224	treatment	abstract|animal[78]	giv|giv[78]	coref	11-19
10-12	1225-1230	group	animal[78]	giv[78]	_	_
10-13	1231-1237	during	_	_	_	_
10-14	1238-1241	the	event[79]	new[79]	_	_
10-15	1242-1247	whole	event[79]	new[79]	_	_
10-16	1248-1258	experiment	event[79]	new[79]	_	_
10-17	1259-1260	.	_	_	_	_

#Text=After four weeks of exposure , no significant changes in body weight were observed between the control and treatment groups after rac -metalaxyl and metalaxyl-M exposure .
11-1	1261-1266	After	_	_	_	_
11-2	1267-1271	four	time[80]	new[80]	_	_
11-3	1272-1277	weeks	time[80]	new[80]	_	_
11-4	1278-1280	of	time[80]	new[80]	_	_
11-5	1281-1289	exposure	time[80]|event	new[80]|giv	coref	11-22[89_0]
11-6	1290-1291	,	_	_	_	_
11-7	1292-1294	no	abstract[82]	giv[82]	_	_
11-8	1295-1306	significant	abstract[82]	giv[82]	_	_
11-9	1307-1314	changes	abstract[82]	giv[82]	_	_
11-10	1315-1317	in	abstract[82]	giv[82]	_	_
11-11	1318-1322	body	abstract[82]|object|abstract[84]	giv[82]|new|new[84]	_	_
11-12	1323-1329	weight	abstract[82]|abstract[84]	giv[82]|new[84]	_	_
11-13	1330-1334	were	_	_	_	_
11-14	1335-1343	observed	_	_	_	_
11-15	1344-1351	between	_	_	_	_
11-16	1352-1355	the	animal[87]	new[87]	_	_
11-17	1356-1363	control	abstract|animal[87]	new|new[87]	_	_
11-18	1364-1367	and	animal[87]	new[87]	_	_
11-19	1368-1377	treatment	abstract|animal[87]	giv|new[87]	_	_
11-20	1378-1384	groups	animal[87]	new[87]	_	_
11-21	1385-1390	after	_	_	_	_
11-22	1391-1394	rac	substance|event[89]	giv|giv[89]	coref|coref	12-5|13-4[100_89]
11-23	1395-1405	-metalaxyl	event[89]	giv[89]	_	_
11-24	1406-1409	and	event[89]	giv[89]	_	_
11-25	1410-1421	metalaxyl-M	event[89]	giv[89]	_	_
11-26	1422-1430	exposure	event[89]	giv[89]	_	_
11-27	1431-1432	.	_	_	_	_

#Text=Histopathology examination showed that rac -metalaxyl and metalaxyl-M can both induce hepatocellular inflammation , necrosis , and vacuolation in mice .
12-1	1433-1447	Histopathology	place|abstract[91]	new|new[91]	_	_
12-2	1448-1459	examination	abstract[91]	new[91]	_	_
12-3	1460-1466	showed	_	_	_	_
12-4	1467-1471	that	_	_	_	_
12-5	1472-1475	rac	substance	giv	coref	13-4
12-6	1476-1486	-metalaxyl	_	_	_	_
12-7	1487-1490	and	_	_	_	_
12-8	1491-1502	metalaxyl-M	substance	giv	coref	14-3
12-9	1503-1506	can	_	_	_	_
12-10	1507-1511	both	_	_	_	_
12-11	1512-1518	induce	_	_	_	_
12-12	1519-1533	hepatocellular	event[94]	new[94]	_	_
12-13	1534-1546	inflammation	event[94]	new[94]	_	_
12-14	1547-1548	,	_	_	_	_
12-15	1549-1557	necrosis	abstract	new	_	_
12-16	1558-1559	,	_	_	_	_
12-17	1560-1563	and	_	_	_	_
12-18	1564-1575	vacuolation	event	new	_	_
12-19	1576-1578	in	_	_	_	_
12-20	1579-1583	mice	animal	new	coref	13-13
12-21	1584-1585	.	_	_	_	_

#Text=Such results suggested rac -metalaxyl and metalaxyl-M exposure caused liver dysfunction in mice .
13-1	1586-1590	Such	abstract[98]	giv[98]	coref	27-5[195_98]
13-2	1591-1598	results	abstract[98]	giv[98]	_	_
13-3	1599-1608	suggested	_	_	_	_
13-4	1609-1612	rac	substance|event[100]	giv|giv[100]	coref|coref	14-9[107_0]|19-13[130_100]
13-5	1613-1623	-metalaxyl	event[100]	giv[100]	_	_
13-6	1624-1627	and	event[100]	giv[100]	_	_
13-7	1628-1639	metalaxyl-M	event[100]	giv[100]	_	_
13-8	1640-1648	exposure	event[100]	giv[100]	_	_
13-9	1649-1655	caused	_	_	_	_
13-10	1656-1661	liver	object|event[102]	giv|new[102]	coref	14-6
13-11	1662-1673	dysfunction	event[102]	new[102]	_	_
13-12	1674-1676	in	_	_	_	_
13-13	1677-1681	mice	animal	giv	coref	16-12
13-14	1682-1683	.	_	_	_	_

#Text=Moreover , metalaxyl-M induced greater liver damage than rac -metalaxyl at the same dosage .
14-1	1684-1692	Moreover	_	_	_	_
14-2	1693-1694	,	_	_	_	_
14-3	1695-1706	metalaxyl-M	substance	giv	coref	22-23
14-4	1707-1714	induced	_	_	_	_
14-5	1715-1722	greater	event[106]	new[106]	_	_
14-6	1723-1728	liver	object|event[106]	giv|new[106]	coref	15-1[109_0]
14-7	1729-1735	damage	event[106]	new[106]	_	_
14-8	1736-1740	than	_	_	_	_
14-9	1741-1744	rac	substance[107]	giv[107]	coref	19-13[0_107]
14-10	1745-1755	-metalaxyl	substance[107]	giv[107]	_	_
14-11	1756-1758	at	_	_	_	_
14-12	1759-1762	the	substance[108]	new[108]	_	_
14-13	1763-1767	same	substance[108]	new[108]	_	_
14-14	1768-1774	dosage	substance[108]	new[108]	_	_
14-15	1775-1776	.	_	_	_	_

#Text=The liver is a fundamental and essential organ for metabolism and detoxification of xenobiotics with abundant cytochrome P450 enzymes .
15-1	1777-1780	The	object[109]	giv[109]	coref	15-4[110_109]
15-2	1781-1786	liver	object[109]	giv[109]	_	_
15-3	1787-1789	is	_	_	_	_
15-4	1790-1791	a	object[110]	giv[110]	coref	16-4[118_110]
15-5	1792-1803	fundamental	object[110]	giv[110]	_	_
15-6	1804-1807	and	object[110]	giv[110]	_	_
15-7	1808-1817	essential	object[110]	giv[110]	_	_
15-8	1818-1823	organ	object[110]	giv[110]	_	_
15-9	1824-1827	for	object[110]	giv[110]	_	_
15-10	1828-1838	metabolism	object[110]|abstract	giv[110]|giv	coref	18-1[123_0]
15-11	1839-1842	and	object[110]	giv[110]	_	_
15-12	1843-1857	detoxification	object[110]|abstract[112]	giv[110]|new[112]	_	_
15-13	1858-1860	of	object[110]|abstract[112]	giv[110]|new[112]	_	_
15-14	1861-1872	xenobiotics	object[110]|abstract[112]|substance	giv[110]|new[112]|new	_	_
15-15	1873-1877	with	object[110]|abstract[112]	giv[110]|new[112]	_	_
15-16	1878-1886	abundant	object[110]|abstract[112]|abstract[116]	giv[110]|new[112]|new[116]	coref	22-28[164_116]
15-17	1887-1897	cytochrome	object[110]|abstract[112]|abstract|abstract[115]|abstract[116]	giv[110]|new[112]|new|new[115]|new[116]	_	_
15-18	1898-1902	P450	object[110]|abstract[112]|abstract[115]|abstract[116]	giv[110]|new[112]|new[115]|new[116]	_	_
15-19	1903-1910	enzymes	object[110]|abstract[112]|abstract[116]	giv[110]|new[112]|new[116]	_	_
15-20	1911-1912	.	_	_	_	_

#Text=The damages of the liver may greatly affect the detoxification of mice .
16-1	1913-1916	The	event[117]	giv[117]	_	_
16-2	1917-1924	damages	event[117]	giv[117]	_	_
16-3	1925-1927	of	event[117]	giv[117]	_	_
16-4	1928-1931	the	event[117]|object[118]	giv[117]|giv[118]	coref	21-18[0_118]
16-5	1932-1937	liver	event[117]|object[118]	giv[117]|giv[118]	_	_
16-6	1938-1941	may	_	_	_	_
16-7	1942-1949	greatly	_	_	_	_
16-8	1950-1956	affect	_	_	_	_
16-9	1957-1960	the	event[119]	new[119]	_	_
16-10	1961-1975	detoxification	event[119]	new[119]	_	_
16-11	1976-1978	of	event[119]	new[119]	_	_
16-12	1979-1983	mice	event[119]|animal	new[119]|giv	coref	19-10
16-13	1984-1985	.	_	_	_	_

#Text=3.2.
17-1	1986-1990	3.2.	abstract	new	_	_

#Text=Energy Metabolism
18-1	1991-1997	Energy	abstract|abstract[123]	giv|giv[123]	coref|coref	19-4|19-4[126_123]
18-2	1998-2008	Metabolism	abstract[123]	giv[123]	_	_

#Text=Metabolites involved in energy metabolism were significant changed in mice urine after rac -metalaxyl and metalaxyl-M exposure , including citrate , succinate , lactate , alanine , pyruvate , and acetate .
19-1	2009-2020	Metabolites	substance[124]	giv[124]	coref	20-1[137_124]
19-2	2021-2029	involved	substance[124]	giv[124]	_	_
19-3	2030-2032	in	substance[124]	giv[124]	_	_
19-4	2033-2039	energy	substance[124]|abstract|abstract[126]	giv[124]|giv|giv[126]	coref|coref	20-7|20-15[143_126]
19-5	2040-2050	metabolism	substance[124]|abstract[126]	giv[124]|giv[126]	_	_
19-6	2051-2055	were	_	_	_	_
19-7	2056-2067	significant	_	_	_	_
19-8	2068-2075	changed	_	_	_	_
19-9	2076-2078	in	_	_	_	_
19-10	2079-2083	mice	animal|substance[128]	giv|giv[128]	coref|coref	22-16[159_128]|22-19[160_0]
19-11	2084-2089	urine	substance[128]	giv[128]	_	_
19-12	2090-2095	after	_	_	_	_
19-13	2096-2099	rac	substance|event[130]	giv|giv[130]	coref|coref	27-16|27-16[201_130]
19-14	2100-2110	-metalaxyl	event[130]	giv[130]	_	_
19-15	2111-2114	and	event[130]	giv[130]	_	_
19-16	2115-2126	metalaxyl-M	event[130]	giv[130]	_	_
19-17	2127-2135	exposure	event[130]	giv[130]	_	_
19-18	2136-2137	,	event[130]	giv[130]	_	_
19-19	2138-2147	including	event[130]	giv[130]	_	_
19-20	2148-2155	citrate	event[130]|substance	giv[130]|giv	coref	21-1
19-21	2156-2157	,	event[130]	giv[130]	_	_
19-22	2158-2167	succinate	event[130]|substance	giv[130]|new	coref	21-3
19-23	2168-2169	,	event[130]	giv[130]	_	_
19-24	2170-2177	lactate	event[130]|substance	giv[130]|new	coref	23-13
19-25	2178-2179	,	event[130]	giv[130]	_	_
19-26	2180-2187	alanine	event[130]|substance	giv[130]|new	coref	23-15
19-27	2188-2189	,	event[130]	giv[130]	_	_
19-28	2190-2198	pyruvate	event[130]|abstract	giv[130]|giv	coref	20-15
19-29	2199-2200	,	event[130]	giv[130]	_	_
19-30	2201-2204	and	event[130]	giv[130]	_	_
19-31	2205-2212	acetate	event[130]|substance	giv[130]|new	_	_
19-32	2213-2214	.	_	_	_	_

#Text=These metabolites are highly related to energy pathways , including the TCA cycle , pyruvate metabolism , and glycolysis or gluconeogenesis .
20-1	2215-2220	These	substance[137]	giv[137]	coref	34-1[237_137]
20-2	2221-2232	metabolites	substance[137]	giv[137]	_	_
20-3	2233-2236	are	_	_	_	_
20-4	2237-2243	highly	_	_	_	_
20-5	2244-2251	related	_	_	_	_
20-6	2252-2254	to	_	_	_	_
20-7	2255-2261	energy	abstract|abstract[139]	giv|giv[139]	coref	22-41
20-8	2262-2270	pathways	abstract[139]	giv[139]	_	_
20-9	2271-2272	,	abstract[139]	giv[139]	_	_
20-10	2273-2282	including	abstract[139]	giv[139]	_	_
20-11	2283-2286	the	abstract[139]|abstract[141]	giv[139]|giv[141]	coref	21-9[151_141]
20-12	2287-2290	TCA	abstract[139]|abstract|abstract[141]	giv[139]|giv|giv[141]	coref	21-10
20-13	2291-2296	cycle	abstract[139]|abstract[141]	giv[139]|giv[141]	_	_
20-14	2297-2298	,	abstract[139]	giv[139]	_	_
20-15	2299-2307	pyruvate	abstract[139]|abstract|abstract[143]	giv[139]|giv|giv[143]	coref|coref	22-41[169_143]|23-8
20-16	2308-2318	metabolism	abstract[139]|abstract[143]	giv[139]|giv[143]	_	_
20-17	2319-2320	,	abstract[139]	giv[139]	_	_
20-18	2321-2324	and	abstract[139]	giv[139]	_	_
20-19	2325-2335	glycolysis	abstract[139]|abstract	giv[139]|giv	_	_
20-20	2336-2338	or	abstract[139]	giv[139]	_	_
20-21	2339-2354	gluconeogenesis	abstract[139]|abstract	giv[139]|giv	_	_
20-22	2355-2356	.	_	_	_	_

#Text=Citrate and succinate are the main intermediates in the TCA cycle , which is mainly appeared in liver mitochondria .
21-1	2357-2364	Citrate	substance|substance[147]	giv|new[147]	coref|coref	22-12|22-12[157_147]
21-2	2365-2368	and	substance[147]	new[147]	_	_
21-3	2369-2378	succinate	substance[147]|substance	new[147]|giv	coref	21-5[149_0]
21-4	2379-2382	are	_	_	_	_
21-5	2383-2386	the	substance[149]	giv[149]	coref	22-14[0_149]
21-6	2387-2391	main	substance[149]	giv[149]	_	_
21-7	2392-2405	intermediates	substance[149]	giv[149]	_	_
21-8	2406-2408	in	substance[149]	giv[149]	_	_
21-9	2409-2412	the	substance[149]|abstract[151]	giv[149]|giv[151]	coref	22-32[166_151]
21-10	2413-2416	TCA	substance[149]|abstract|abstract[151]	giv[149]|giv|giv[151]	coref	22-33
21-11	2417-2422	cycle	substance[149]|abstract[151]	giv[149]|giv[151]	_	_
21-12	2423-2424	,	substance[149]|abstract[151]	giv[149]|giv[151]	_	_
21-13	2425-2430	which	substance[149]|abstract[151]	giv[149]|giv[151]	_	_
21-14	2431-2433	is	substance[149]|abstract[151]	giv[149]|giv[151]	_	_
21-15	2434-2440	mainly	substance[149]|abstract[151]	giv[149]|giv[151]	_	_
21-16	2441-2449	appeared	substance[149]|abstract[151]	giv[149]|giv[151]	_	_
21-17	2450-2452	in	substance[149]|abstract[151]	giv[149]|giv[151]	_	_
21-18	2453-2458	liver	substance[149]|abstract[151]|object|animal[153]	giv[149]|giv[151]|giv|new[153]	_	_
21-19	2459-2471	mitochondria	substance[149]|abstract[151]|animal[153]	giv[149]|giv[151]|new[153]	_	_
21-20	2472-2473	.	_	_	_	_

#Text=Although other factors cannot be excluded , the increased levels of citrate and succinate in the urine of metalaxyl-M-treated mice indicated that metalaxyl-M affected the activity of mitochondria enzymes involved in the TCA cycle , resulting in the enhancement of energy metabolism in treated mice .
22-1	2474-2482	Although	_	_	_	_
22-2	2483-2488	other	abstract[154]	new[154]	_	_
22-3	2489-2496	factors	abstract[154]	new[154]	_	_
22-4	2497-2503	cannot	_	_	_	_
22-5	2504-2506	be	_	_	_	_
22-6	2507-2515	excluded	_	_	_	_
22-7	2516-2517	,	_	_	_	_
22-8	2518-2521	the	abstract[155]	new[155]	_	_
22-9	2522-2531	increased	abstract[155]	new[155]	_	_
22-10	2532-2538	levels	abstract[155]	new[155]	_	_
22-11	2539-2541	of	abstract[155]	new[155]	_	_
22-12	2542-2549	citrate	abstract[155]|substance|substance[157]	new[155]|giv|giv[157]	coref	24-21
22-13	2550-2553	and	abstract[155]|substance[157]	new[155]|giv[157]	_	_
22-14	2554-2563	succinate	abstract[155]|substance[157]|substance	new[155]|giv[157]|giv	_	_
22-15	2564-2566	in	abstract[155]	new[155]	_	_
22-16	2567-2570	the	abstract[155]|substance[159]	new[155]|giv[159]	coref	37-5[0_159]
22-17	2571-2576	urine	abstract[155]|substance[159]	new[155]|giv[159]	_	_
22-18	2577-2579	of	abstract[155]|substance[159]	new[155]|giv[159]	_	_
22-19	2580-2599	metalaxyl-M-treated	abstract[155]|substance[159]|animal[160]	new[155]|giv[159]|giv[160]	coref	22-44[170_160]
22-20	2600-2604	mice	abstract[155]|substance[159]|animal[160]	new[155]|giv[159]|giv[160]	_	_
22-21	2605-2614	indicated	_	_	_	_
22-22	2615-2619	that	_	_	_	_
22-23	2620-2631	metalaxyl-M	substance	giv	coref	30-5
22-24	2632-2640	affected	_	_	_	_
22-25	2641-2644	the	abstract[162]	new[162]	_	_
22-26	2645-2653	activity	abstract[162]	new[162]	_	_
22-27	2654-2656	of	abstract[162]	new[162]	_	_
22-28	2657-2669	mitochondria	abstract[162]|animal|abstract[164]	new[162]|new|giv[164]	_	_
22-29	2670-2677	enzymes	abstract[162]|abstract[164]	new[162]|giv[164]	_	_
22-30	2678-2686	involved	abstract[162]|abstract[164]	new[162]|giv[164]	_	_
22-31	2687-2689	in	abstract[162]|abstract[164]	new[162]|giv[164]	_	_
22-32	2690-2693	the	abstract[162]|abstract[164]|abstract[166]	new[162]|giv[164]|giv[166]	_	_
22-33	2694-2697	TCA	abstract[162]|abstract[164]|abstract|abstract[166]	new[162]|giv[164]|giv|giv[166]	_	_
22-34	2698-2703	cycle	abstract[162]|abstract[164]|abstract[166]	new[162]|giv[164]|giv[166]	_	_
22-35	2704-2705	,	_	_	_	_
22-36	2706-2715	resulting	_	_	_	_
22-37	2716-2718	in	_	_	_	_
22-38	2719-2722	the	abstract[167]	new[167]	_	_
22-39	2723-2734	enhancement	abstract[167]	new[167]	_	_
22-40	2735-2737	of	abstract[167]	new[167]	_	_
22-41	2738-2744	energy	abstract[167]|abstract|abstract[169]	new[167]|giv|giv[169]	coref|coref	23-20[177_169]|26-18
22-42	2745-2755	metabolism	abstract[167]|abstract[169]	new[167]|giv[169]	_	_
22-43	2756-2758	in	abstract[167]|abstract[169]	new[167]|giv[169]	_	_
22-44	2759-2766	treated	abstract[167]|abstract[169]|animal[170]	new[167]|giv[169]|giv[170]	coref	27-14[199_170]
22-45	2767-2771	mice	abstract[167]|abstract[169]|animal[170]	new[167]|giv[169]|giv[170]	_	_
22-46	2772-2773	.	_	_	_	_

#Text=In addition , the decreased level of pyruvate and increased levels of lactate and alanine were highly related to pyruvate metabolism .
23-1	2774-2776	In	_	_	_	_
23-2	2777-2785	addition	_	_	_	_
23-3	2786-2787	,	_	_	_	_
23-4	2788-2791	the	abstract[171]	new[171]	_	_
23-5	2792-2801	decreased	abstract[171]	new[171]	_	_
23-6	2802-2807	level	abstract[171]	new[171]	_	_
23-7	2808-2810	of	abstract[171]	new[171]	_	_
23-8	2811-2819	pyruvate	abstract[171]|abstract	new[171]|giv	coref	24-1
23-9	2820-2823	and	_	_	_	_
23-10	2824-2833	increased	abstract[173]	new[173]	_	_
23-11	2834-2840	levels	abstract[173]	new[173]	_	_
23-12	2841-2843	of	abstract[173]	new[173]	_	_
23-13	2844-2851	lactate	abstract[173]|substance|substance[175]	new[173]|giv|new[175]	coref|coref	25-1|25-1[185_175]
23-14	2852-2855	and	abstract[173]|substance[175]	new[173]|new[175]	_	_
23-15	2856-2863	alanine	abstract[173]|substance[175]|substance	new[173]|new[175]|giv	coref	25-3
23-16	2864-2868	were	_	_	_	_
23-17	2869-2875	highly	_	_	_	_
23-18	2876-2883	related	_	_	_	_
23-19	2884-2886	to	_	_	_	_
23-20	2887-2895	pyruvate	abstract[177]	giv[177]	coref	26-17[194_177]
23-21	2896-2906	metabolism	abstract[177]	giv[177]	_	_
23-22	2907-2908	.	_	_	_	_

#Text=Pyruvate could be converted to acetyl-coenzyme A ( COA ) , which is a vital intermediate in the synthesis of citrate .
24-1	2909-2917	Pyruvate	abstract	giv	coref	25-9
24-2	2918-2923	could	_	_	_	_
24-3	2924-2926	be	_	_	_	_
24-4	2927-2936	converted	_	_	_	_
24-5	2937-2939	to	_	_	_	_
24-6	2940-2955	acetyl-coenzyme	substance[179]	new[179]	appos	24-9[0_179]
24-7	2956-2957	A	substance[179]	new[179]	_	_
24-8	2958-2959	(	_	_	_	_
24-9	2960-2963	COA	substance	giv	_	_
24-10	2964-2965	)	_	_	_	_
24-11	2966-2967	,	_	_	_	_
24-12	2968-2973	which	substance[181]	new[181]	_	_
24-13	2974-2976	is	substance[181]	new[181]	_	_
24-14	2977-2978	a	substance[181]	new[181]	_	_
24-15	2979-2984	vital	substance[181]	new[181]	_	_
24-16	2985-2997	intermediate	substance[181]	new[181]	_	_
24-17	2998-3000	in	substance[181]	new[181]	_	_
24-18	3001-3004	the	substance[181]|event[182]	new[181]|new[182]	coref	35-16[251_182]
24-19	3005-3014	synthesis	substance[181]|event[182]	new[181]|new[182]	_	_
24-20	3015-3017	of	substance[181]|event[182]	new[181]|new[182]	_	_
24-21	3018-3025	citrate	substance[181]|event[182]|substance	new[181]|new[182]|giv	_	_
24-22	3026-3027	.	_	_	_	_

#Text=Lactate and alanine can also be converted to pyruvate .
25-1	3028-3035	Lactate	substance|substance[185]	giv|giv[185]	coref|coref	26-3[188_0]|26-3[189_185]
25-2	3036-3039	and	substance[185]	giv[185]	_	_
25-3	3040-3047	alanine	substance[185]|substance	giv[185]|giv	coref	26-7
25-4	3048-3051	can	_	_	_	_
25-5	3052-3056	also	_	_	_	_
25-6	3057-3059	be	_	_	_	_
25-7	3060-3069	converted	_	_	_	_
25-8	3070-3072	to	_	_	_	_
25-9	3073-3081	pyruvate	abstract	giv	_	_
25-10	3082-3083	.	_	_	_	_

#Text=Thus , the increased lactate and alanine could promote the level of acetyl-COA and then up-regulate the energy metabolism .
26-1	3084-3088	Thus	_	_	_	_
26-2	3089-3090	,	_	_	_	_
26-3	3091-3094	the	substance[188]|substance[189]	giv[188]|giv[189]	_	_
26-4	3095-3104	increased	substance[188]|substance[189]	giv[188]|giv[189]	_	_
26-5	3105-3112	lactate	substance[188]|substance[189]	giv[188]|giv[189]	_	_
26-6	3113-3116	and	substance[189]	giv[189]	_	_
26-7	3117-3124	alanine	substance[189]|substance	giv[189]|giv	_	_
26-8	3125-3130	could	_	_	_	_
26-9	3131-3138	promote	_	_	_	_
26-10	3139-3142	the	abstract[191]	new[191]	_	_
26-11	3143-3148	level	abstract[191]	new[191]	_	_
26-12	3149-3151	of	abstract[191]	new[191]	_	_
26-13	3152-3162	acetyl-COA	abstract[191]|substance	new[191]|new	_	_
26-14	3163-3166	and	_	_	_	_
26-15	3167-3171	then	_	_	_	_
26-16	3172-3183	up-regulate	_	_	_	_
26-17	3184-3187	the	abstract[194]	giv[194]	coref	27-11[198_194]
26-18	3188-3194	energy	abstract|abstract[194]	giv|giv[194]	coref	27-11
26-19	3195-3205	metabolism	abstract[194]	giv[194]	_	_
26-20	3206-3207	.	_	_	_	_

#Text=To sum up , these results indicated the enhancement of energy metabolism in mice after rac -metalaxyl and metalaxyl-M exposure .
27-1	3208-3210	To	_	_	_	_
27-2	3211-3214	sum	_	_	_	_
27-3	3215-3217	up	_	_	_	_
27-4	3218-3219	,	_	_	_	_
27-5	3220-3225	these	abstract[195]	giv[195]	_	_
27-6	3226-3233	results	abstract[195]	giv[195]	_	_
27-7	3234-3243	indicated	_	_	_	_
27-8	3244-3247	the	event[196]	new[196]	_	_
27-9	3248-3259	enhancement	event[196]	new[196]	_	_
27-10	3260-3262	of	event[196]	new[196]	_	_
27-11	3263-3269	energy	event[196]|abstract|abstract[198]	new[196]|giv|giv[198]	coref|coref	28-15|28-15[207_198]
27-12	3270-3280	metabolism	event[196]|abstract[198]	new[196]|giv[198]	_	_
27-13	3281-3283	in	event[196]|abstract[198]	new[196]|giv[198]	_	_
27-14	3284-3288	mice	event[196]|abstract[198]|animal[199]	new[196]|giv[198]|giv[199]	_	_
27-15	3289-3294	after	event[196]|abstract[198]|animal[199]	new[196]|giv[198]|giv[199]	_	_
27-16	3295-3298	rac	event[196]|abstract[198]|animal[199]|substance|event[201]	new[196]|giv[198]|giv[199]|giv|giv[201]	coref|coref	28-12[205_0]|31-10[223_201]
27-17	3299-3309	-metalaxyl	event[196]|abstract[198]|animal[199]|event[201]	new[196]|giv[198]|giv[199]|giv[201]	_	_
27-18	3310-3313	and	event[196]|abstract[198]|animal[199]|event[201]	new[196]|giv[198]|giv[199]|giv[201]	_	_
27-19	3314-3325	metalaxyl-M	event[196]|abstract[198]|animal[199]|event[201]	new[196]|giv[198]|giv[199]|giv[201]	_	_
27-20	3326-3334	exposure	event[196]|abstract[198]|animal[199]|event[201]	new[196]|giv[198]|giv[199]|giv[201]	_	_
27-21	3335-3336	.	_	_	_	_

#Text=Furthermore , the perturbation degrees induced by metalaxy-M were higher than rac -metalaxy in energy metabolism .
28-1	3337-3348	Furthermore	_	_	_	_
28-2	3349-3350	,	_	_	_	_
28-3	3351-3354	the	abstract[203]	new[203]	_	_
28-4	3355-3367	perturbation	abstract|abstract[203]	new|new[203]	_	_
28-5	3368-3375	degrees	abstract[203]	new[203]	_	_
28-6	3376-3383	induced	abstract[203]	new[203]	_	_
28-7	3384-3386	by	abstract[203]	new[203]	_	_
28-8	3387-3397	metalaxy-M	abstract[203]|substance	new[203]|new	_	_
28-9	3398-3402	were	_	_	_	_
28-10	3403-3409	higher	_	_	_	_
28-11	3410-3414	than	_	_	_	_
28-12	3415-3418	rac	substance[205]	giv[205]	coref	31-10[0_205]
28-13	3419-3428	-metalaxy	substance[205]	giv[205]	_	_
28-14	3429-3431	in	_	_	_	_
28-15	3432-3438	energy	abstract|abstract[207]	giv|giv[207]	coref	29-2[209_207]
28-16	3439-3449	metabolism	abstract[207]	giv[207]	_	_
28-17	3450-3451	.	_	_	_	_

#Text=3.3. Lipid Metabolism
29-1	3452-3456	3.3.	_	_	_	_
29-2	3457-3462	Lipid	substance|abstract[209]	new|giv[209]	coref|coref	30-8[212_209]|34-7
29-3	3463-3473	Metabolism	abstract[209]	giv[209]	_	_

#Text=In this study , metalaxyl-M induced two lipid metabolism pathway fluctuations including glycerophospholipid metabolism , glyoxylate , and dicarboxylate metabolism .
30-1	3474-3476	In	_	_	_	_
30-2	3477-3481	this	abstract[210]	new[210]	_	_
30-3	3482-3487	study	abstract[210]	new[210]	_	_
30-4	3488-3489	,	_	_	_	_
30-5	3490-3501	metalaxyl-M	substance	giv	coref	32-6
30-6	3502-3509	induced	_	_	_	_
30-7	3510-3513	two	abstract[214]	new[214]	_	_
30-8	3514-3519	lipid	abstract[212]|abstract[213]|abstract[214]	giv[212]|new[213]|new[214]	coref|coref	30-13[216_212]|31-3[221_213]
30-9	3520-3530	metabolism	abstract[212]|abstract[213]|abstract[214]	giv[212]|new[213]|new[214]	_	_
30-10	3531-3538	pathway	abstract[213]|abstract[214]	new[213]|new[214]	_	_
30-11	3539-3551	fluctuations	abstract[214]	new[214]	_	_
30-12	3552-3561	including	abstract[214]	new[214]	_	_
30-13	3562-3581	glycerophospholipid	abstract[214]|object|abstract[216]	new[214]|new|giv[216]	coref	30-19[219_216]
30-14	3582-3592	metabolism	abstract[214]|abstract[216]	new[214]|giv[216]	_	_
30-15	3593-3594	,	abstract[214]	new[214]	_	_
30-16	3595-3605	glyoxylate	abstract[214]|substance	new[214]|new	_	_
30-17	3606-3607	,	abstract[214]	new[214]	_	_
30-18	3608-3611	and	abstract[214]	new[214]	_	_
30-19	3612-3625	dicarboxylate	abstract[214]|object|abstract[219]	new[214]|new|giv[219]	coref	31-4[220_219]
30-20	3626-3636	metabolism	abstract[214]|abstract[219]	new[214]|giv[219]	_	_
30-21	3637-3638	.	_	_	_	_

#Text=However , no lipid metabolism pathway was affected by rac -metalaxyl exposure .
31-1	3639-3646	However	_	_	_	_
31-2	3647-3648	,	_	_	_	_
31-3	3649-3651	no	abstract[221]	giv[221]	_	_
31-4	3652-3657	lipid	abstract[220]|abstract[221]	giv[220]|giv[221]	coref	34-7[239_220]
31-5	3658-3668	metabolism	abstract[220]|abstract[221]	giv[220]|giv[221]	_	_
31-6	3669-3676	pathway	abstract[221]	giv[221]	_	_
31-7	3677-3680	was	_	_	_	_
31-8	3681-3689	affected	_	_	_	_
31-9	3690-3692	by	_	_	_	_
31-10	3693-3696	rac	substance|event[223]	giv|giv[223]	coref	33-1[234_0]
31-11	3697-3707	-metalaxyl	event[223]	giv[223]	_	_
31-12	3708-3716	exposure	event[223]	giv[223]	_	_
31-13	3717-3718	.	_	_	_	_

#Text=According to metabolomics data , metalaxyl-M induced the increased levels of choline and TMAO and decreased levels of PC and GPC .
32-1	3719-3728	According	_	_	_	_
32-2	3729-3731	to	_	_	_	_
32-3	3732-3744	metabolomics	abstract|abstract[225]	new|new[225]	_	_
32-4	3745-3749	data	abstract[225]	new[225]	_	_
32-5	3750-3751	,	_	_	_	_
32-6	3752-3763	metalaxyl-M	substance	giv	coref	37-14
32-7	3764-3771	induced	_	_	_	_
32-8	3772-3775	the	abstract[227]	new[227]	coref	37-1[269_227]
32-9	3776-3785	increased	abstract[227]	new[227]	_	_
32-10	3786-3792	levels	abstract[227]	new[227]	_	_
32-11	3793-3795	of	abstract[227]	new[227]	_	_
32-12	3796-3803	choline	abstract[227]|substance	new[227]|new	coref	35-1
32-13	3804-3807	and	abstract[227]	new[227]	_	_
32-14	3808-3812	TMAO	abstract[227]|substance	new[227]|new	_	_
32-15	3813-3816	and	_	_	_	_
32-16	3817-3826	decreased	abstract[230]	new[230]	_	_
32-17	3827-3833	levels	abstract[230]	new[230]	_	_
32-18	3834-3836	of	abstract[230]	new[230]	_	_
32-19	3837-3839	PC	abstract[230]|abstract|abstract[232]	new[230]|new|new[232]	coref|coref	38-1|38-1[276_232]
32-20	3840-3843	and	abstract[230]|abstract[232]	new[230]|new[232]	_	_
32-21	3844-3847	GPC	abstract[230]|abstract[232]|abstract	new[230]|new[232]|new	coref	33-9
32-22	3848-3849	.	_	_	_	_

#Text=Rac -metalaxyl only induced the decreased level of GPC .
33-1	3850-3853	Rac	substance[234]	giv[234]	_	_
33-2	3854-3864	-metalaxyl	substance[234]	giv[234]	_	_
33-3	3865-3869	only	_	_	_	_
33-4	3870-3877	induced	_	_	_	_
33-5	3878-3881	the	abstract[235]	new[235]	coref	34-14[242_235]
33-6	3882-3891	decreased	abstract[235]	new[235]	_	_
33-7	3892-3897	level	abstract[235]	new[235]	_	_
33-8	3898-3900	of	abstract[235]	new[235]	_	_
33-9	3901-3904	GPC	abstract[235]|abstract	new[235]|giv	coref	38-3
33-10	3905-3906	.	_	_	_	_

#Text=Such metabolites were all related to lipid metabolism and had essential effect on cholesterol level in digestive system .
34-1	3907-3911	Such	substance[237]	giv[237]	coref	38-8[278_237]
34-2	3912-3923	metabolites	substance[237]	giv[237]	_	_
34-3	3924-3928	were	_	_	_	_
34-4	3929-3932	all	_	_	_	_
34-5	3933-3940	related	_	_	_	_
34-6	3941-3943	to	_	_	_	_
34-7	3944-3949	lipid	substance|abstract[239]	giv|giv[239]	coref|coref	35-10|35-13[249_239]
34-8	3950-3960	metabolism	abstract[239]	giv[239]	_	_
34-9	3961-3964	and	_	_	_	_
34-10	3965-3968	had	_	_	_	_
34-11	3969-3978	essential	abstract[240]	new[240]	_	_
34-12	3979-3985	effect	abstract[240]	new[240]	_	_
34-13	3986-3988	on	abstract[240]	new[240]	_	_
34-14	3989-4000	cholesterol	abstract[240]|substance|abstract[242]	new[240]|new|giv[242]	_	_
34-15	4001-4006	level	abstract[240]|abstract[242]	new[240]|giv[242]	_	_
34-16	4007-4009	in	abstract[240]|abstract[242]	new[240]|giv[242]	_	_
34-17	4010-4019	digestive	abstract[240]|abstract[242]|abstract[243]	new[240]|giv[242]|new[243]	_	_
34-18	4020-4026	system	abstract[240]|abstract[242]|abstract[243]	new[240]|giv[242]|new[243]	_	_
34-19	4027-4028	.	_	_	_	_

#Text=Choline is an important nutrient that is required for lipid transport , methyl-group metabolism , neurotransmitter synthesis , cell membrane structure , and signaling .
35-1	4029-4036	Choline	substance	giv	coref	35-3[245_0]
35-2	4037-4039	is	_	_	_	_
35-3	4040-4042	an	substance[245]	giv[245]	coref	36-4[0_245]
35-4	4043-4052	important	substance[245]	giv[245]	_	_
35-5	4053-4061	nutrient	substance[245]	giv[245]	_	_
35-6	4062-4066	that	substance[245]	giv[245]	_	_
35-7	4067-4069	is	substance[245]	giv[245]	_	_
35-8	4070-4078	required	substance[245]	giv[245]	_	_
35-9	4079-4082	for	substance[245]	giv[245]	_	_
35-10	4083-4088	lipid	substance[245]|substance|abstract[247]	giv[245]|giv|new[247]	coref	36-27
35-11	4089-4098	transport	substance[245]|abstract[247]	giv[245]|new[247]	_	_
35-12	4099-4100	,	substance[245]	giv[245]	_	_
35-13	4101-4113	methyl-group	substance[245]|object|abstract[249]	giv[245]|new|giv[249]	coref	36-27[267_249]
35-14	4114-4124	metabolism	substance[245]|abstract[249]	giv[245]|giv[249]	_	_
35-15	4125-4126	,	substance[245]	giv[245]	_	_
35-16	4127-4143	neurotransmitter	substance[245]|abstract|event[251]	giv[245]|new|giv[251]	_	_
35-17	4144-4153	synthesis	substance[245]|event[251]	giv[245]|giv[251]	_	_
35-18	4154-4155	,	substance[245]	giv[245]	_	_
35-19	4156-4160	cell	substance[245]|place|abstract[254]	giv[245]|new|new[254]	coref	36-9
35-20	4161-4169	membrane	substance[245]|object|abstract[254]	giv[245]|new|new[254]	coref	36-24[265_0]
35-21	4170-4179	structure	substance[245]|abstract[254]	giv[245]|new[254]	_	_
35-22	4180-4181	,	substance[245]	giv[245]	_	_
35-23	4182-4185	and	substance[245]	giv[245]	_	_
35-24	4186-4195	signaling	substance[245]|abstract	giv[245]|new	_	_
35-25	4196-4197	.	_	_	_	_

#Text=In addition , choline is a constituent of cell membranes and lipoprotein phospholipids , which play an important role in the integrity of cell membrane and lipid metabolism .
36-1	4198-4200	In	_	_	_	_
36-2	4201-4209	addition	_	_	_	_
36-3	4210-4211	,	_	_	_	_
36-4	4212-4219	choline	substance	giv	coref	36-6[257_0]
36-5	4220-4222	is	_	_	_	_
36-6	4223-4224	a	substance[257]	giv[257]	coref	37-2[0_257]
36-7	4225-4236	constituent	substance[257]	giv[257]	_	_
36-8	4237-4239	of	substance[257]	giv[257]	_	_
36-9	4240-4244	cell	substance[257]|place|place[259]	giv[257]|giv|new[259]	coref|coref	36-24|39-13[290_259]
36-10	4245-4254	membranes	substance[257]|place[259]	giv[257]|new[259]	_	_
36-11	4255-4258	and	substance[257]	giv[257]	_	_
36-12	4259-4270	lipoprotein	substance[257]|substance|abstract[261]	giv[257]|new|new[261]	_	_
36-13	4271-4284	phospholipids	substance[257]|abstract[261]	giv[257]|new[261]	_	_
36-14	4285-4286	,	substance[257]|abstract[261]	giv[257]|new[261]	_	_
36-15	4287-4292	which	substance[257]|abstract[261]	giv[257]|new[261]	_	_
36-16	4293-4297	play	substance[257]|abstract[261]	giv[257]|new[261]	_	_
36-17	4298-4300	an	substance[257]|abstract[261]|abstract[262]	giv[257]|new[261]|new[262]	_	_
36-18	4301-4310	important	substance[257]|abstract[261]|abstract[262]	giv[257]|new[261]|new[262]	_	_
36-19	4311-4315	role	substance[257]|abstract[261]|abstract[262]	giv[257]|new[261]|new[262]	_	_
36-20	4316-4318	in	substance[257]|abstract[261]|abstract[262]	giv[257]|new[261]|new[262]	_	_
36-21	4319-4322	the	substance[257]|abstract[261]|abstract[262]|abstract[263]	giv[257]|new[261]|new[262]|new[263]	_	_
36-22	4323-4332	integrity	substance[257]|abstract[261]|abstract[262]|abstract[263]	giv[257]|new[261]|new[262]|new[263]	_	_
36-23	4333-4335	of	substance[257]|abstract[261]|abstract[262]|abstract[263]	giv[257]|new[261]|new[262]|new[263]	_	_
36-24	4336-4340	cell	substance[257]|abstract[261]|abstract[262]|abstract[263]|place|object[265]	giv[257]|new[261]|new[262]|new[263]|giv|giv[265]	coref|coref	37-9[0_265]|39-13
36-25	4341-4349	membrane	substance[257]|abstract[261]|abstract[262]|abstract[263]|object[265]	giv[257]|new[261]|new[262]|new[263]|giv[265]	_	_
36-26	4350-4353	and	substance[257]|abstract[261]|abstract[262]|abstract[263]	giv[257]|new[261]|new[262]|new[263]	_	_
36-27	4354-4359	lipid	substance[257]|abstract[261]|abstract[262]|abstract[263]|substance|abstract[267]	giv[257]|new[261]|new[262]|new[263]|giv|giv[267]	_	_
36-28	4360-4370	metabolism	substance[257]|abstract[261]|abstract[262]|abstract[263]|abstract[267]	giv[257]|new[261]|new[262]|new[263]|giv[267]	_	_
36-29	4371-4372	.	_	_	_	_

#Text=Increased choline levels in urine samples suggested the membrane fluidity was disrupted by metalaxyl-M .
37-1	4373-4382	Increased	abstract[269]	giv[269]	_	_
37-2	4383-4390	choline	substance|abstract[269]	giv|giv[269]	coref	38-15
37-3	4391-4397	levels	abstract[269]	giv[269]	_	_
37-4	4398-4400	in	abstract[269]	giv[269]	_	_
37-5	4401-4406	urine	abstract[269]|substance|object[271]	giv[269]|giv|new[271]	_	_
37-6	4407-4414	samples	abstract[269]|object[271]	giv[269]|new[271]	_	_
37-7	4415-4424	suggested	_	_	_	_
37-8	4425-4428	the	substance[273]	new[273]	_	_
37-9	4429-4437	membrane	object|substance[273]	giv|new[273]	_	_
37-10	4438-4446	fluidity	substance[273]	new[273]	_	_
37-11	4447-4450	was	_	_	_	_
37-12	4451-4460	disrupted	_	_	_	_
37-13	4461-4463	by	_	_	_	_
37-14	4464-4475	metalaxyl-M	substance	giv	coref	40-19
37-15	4476-4477	.	_	_	_	_

#Text=PC and GPC are known to be important endogenous metabolites related to maintenance of choline homeostasis and bile acids excretion .
38-1	4478-4480	PC	abstract|abstract[276]	giv|giv[276]	coref|coref	39-3|39-3[286_276]
38-2	4481-4484	and	abstract[276]	giv[276]	_	_
38-3	4485-4488	GPC	abstract[276]|abstract	giv[276]|giv	coref	39-6
38-4	4489-4492	are	_	_	_	_
38-5	4493-4498	known	_	_	_	_
38-6	4499-4501	to	_	_	_	_
38-7	4502-4504	be	_	_	_	_
38-8	4505-4514	important	substance[278]	giv[278]	_	_
38-9	4515-4525	endogenous	substance[278]	giv[278]	_	_
38-10	4526-4537	metabolites	substance[278]	giv[278]	_	_
38-11	4538-4545	related	substance[278]	giv[278]	_	_
38-12	4546-4548	to	substance[278]	giv[278]	_	_
38-13	4549-4560	maintenance	substance[278]|abstract[279]	giv[278]|new[279]	_	_
38-14	4561-4563	of	substance[278]|abstract[279]	giv[278]|new[279]	_	_
38-15	4564-4571	choline	substance[278]|abstract[279]|substance|abstract[281]	giv[278]|new[279]|giv|new[281]	_	_
38-16	4572-4583	homeostasis	substance[278]|abstract[279]|abstract[281]	giv[278]|new[279]|new[281]	_	_
38-17	4584-4587	and	substance[278]|abstract[279]	giv[278]|new[279]	_	_
38-18	4588-4592	bile	substance[278]|abstract[279]|object|substance[283]|abstract[284]	giv[278]|new[279]|new|new[283]|new[284]	_	_
38-19	4593-4598	acids	substance[278]|abstract[279]|substance[283]|abstract[284]	giv[278]|new[279]|new[283]|new[284]	_	_
38-20	4599-4608	excretion	substance[278]|abstract[279]|abstract[284]	giv[278]|new[279]|new[284]	_	_
38-21	4609-4610	.	_	_	_	_

#Text=Moreover , PC , and GPC are not only essential components of cell membranes , but also protect cell from oxidative stress and lipotoxicity .
39-1	4611-4619	Moreover	_	_	_	_
39-2	4620-4621	,	_	_	_	_
39-3	4622-4624	PC	abstract|abstract[286]	giv|giv[286]	coref|coref	40-5|40-5[298_286]
39-4	4625-4626	,	abstract[286]	giv[286]	_	_
39-5	4627-4630	and	abstract[286]	giv[286]	_	_
39-6	4631-4634	GPC	abstract[286]|abstract	giv[286]|giv	coref	40-7
39-7	4635-4638	are	_	_	_	_
39-8	4639-4642	not	_	_	_	_
39-9	4643-4647	only	abstract[288]	new[288]	_	_
39-10	4648-4657	essential	abstract[288]	new[288]	_	_
39-11	4658-4668	components	abstract[288]	new[288]	_	_
39-12	4669-4671	of	abstract[288]	new[288]	_	_
39-13	4672-4676	cell	abstract[288]|place|place[290]	new[288]|giv|giv[290]	coref	39-19
39-14	4677-4686	membranes	abstract[288]|place[290]	new[288]|giv[290]	_	_
39-15	4687-4688	,	_	_	_	_
39-16	4689-4692	but	_	_	_	_
39-17	4693-4697	also	_	_	_	_
39-18	4698-4705	protect	_	_	_	_
39-19	4706-4710	cell	place	giv	_	_
39-20	4711-4715	from	_	_	_	_
39-21	4716-4725	oxidative	abstract|abstract[293]|abstract[294]	new|new[293]|new[294]	coref|coref	40-13[301_293]|40-13[302_294]
39-22	4726-4732	stress	abstract[293]|abstract[294]	new[293]|new[294]	_	_
39-23	4733-4736	and	abstract[294]	new[294]	_	_
39-24	4737-4749	lipotoxicity	abstract[294]|substance	new[294]|new	coref	40-16[303_0]
39-25	4750-4751	.	_	_	_	_

#Text=The decreased levels of PC and GPC may be good indicators of oxidative stress and lipotoxicity induced by metalaxyl-M .
40-1	4752-4755	The	abstract[296]	new[296]	coref	40-10[300_296]
40-2	4756-4765	decreased	abstract[296]	new[296]	_	_
40-3	4766-4772	levels	abstract[296]	new[296]	_	_
40-4	4773-4775	of	abstract[296]	new[296]	_	_
40-5	4776-4778	PC	abstract[296]|abstract|abstract[298]	new[296]|giv|giv[298]	_	_
40-6	4779-4782	and	abstract[296]|abstract[298]	new[296]|giv[298]	_	_
40-7	4783-4786	GPC	abstract[296]|abstract[298]|abstract	new[296]|giv[298]|giv	_	_
40-8	4787-4790	may	_	_	_	_
40-9	4791-4793	be	_	_	_	_
40-10	4794-4798	good	abstract[300]	giv[300]	_	_
40-11	4799-4809	indicators	abstract[300]	giv[300]	_	_
40-12	4810-4812	of	abstract[300]	giv[300]	_	_
40-13	4813-4822	oxidative	abstract[300]|abstract[301]|abstract[302]	giv[300]|giv[301]|giv[302]	_	_
40-14	4823-4829	stress	abstract[300]|abstract[301]|abstract[302]	giv[300]|giv[301]|giv[302]	_	_
40-15	4830-4833	and	abstract[300]|abstract[302]	giv[300]|giv[302]	_	_
40-16	4834-4846	lipotoxicity	abstract[300]|abstract[302]|substance[303]	giv[300]|giv[302]|giv[303]	_	_
40-17	4847-4854	induced	abstract[300]|abstract[302]|substance[303]	giv[300]|giv[302]|giv[303]	_	_
40-18	4855-4857	by	abstract[300]|abstract[302]|substance[303]	giv[300]|giv[302]|giv[303]	_	_
40-19	4858-4869	metalaxyl-M	abstract[300]|abstract[302]|substance[303]|substance	giv[300]|giv[302]|giv[303]|giv	_	_
40-20	4870-4871	.	_	_	_	_
